Jill Autry
Optometrist · Bellaire, TXNPI 1922001270
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $118,307 of the $171,324 with a category attached, or 69.1%. AbbVie accounts for 86.0% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2021 at $46,765 and has fallen 86.1% since, to $6,514 in 2025. Among optometrist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 477 payments — averaging $359.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$147K
- Eyevance Pharmaceuticals LLC$12K
- Sun Pharmaceutical Industries Inc.$5K
- Sight Sciences, Inc.$1K
- Alcon$1K
- Johnson & Johnson Surgical Vision, Inc.$1K
- plus $4K from 22 others
What the payments were for
- Consulting fees$38,89423%
- Speaking & faculty fees$118,30769%
- Travel & lodging$3,4602%
- Food & beverage$10,5586%
- Entertainment$1060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 267 | $147,353 |
| Eyevance Pharmaceuticals LLC | 21 | $11,714 |
| Sun Pharmaceutical Industries Inc. | 39 | $4,785 |
| Sight Sciences, Inc. | 10 | $1,306 |
| Alcon | 27 | $1,228 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $1,022 |
| Ivantis, Inc | 1 | $675 |
| Novartis | 25 | $639 |
| Tarsus Pharmaceuticals, Inc. | 10 | $378 |
| Oyster Point Pharma, Inc. | 13 | $370 |
| Aerie Pharmaceuticals, Inc. | 6 | $312 |
| Optos, Inc. | 4 | $280 |
| Dompe US, Inc. | 4 | $208 |
| Kala Pharmaceuticals, Inc. | 8 | $186 |
| Ocular Therapeutix, Inc. | 6 | $150 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $149 |
| Biotissue Holdings Inc. | 6 | $127 |
| Bausch & Lomb Americas Inc. | 5 | $84 |
| Amgen(2 entities) | 3 | $71 |
| Alcon Research LLC | 1 | $53 |
| Regeneron Healthcare Solutions, Inc. | 3 | $48 |
| Harrow Eye, LLC | 2 | $47 |
| Mallinckrodt Hospital Products Inc. | 2 | $45 |
| Biogen | 1 | $29 |
| Glaukos Corporation | 1 | $27 |
| Shire North American Group Inc | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| NEW World Medical,inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIGAN$28,624
- VUITY$25,591
- RESTASIS MULTIDOSE$20,767
- DURYSTA$18,706
- XEN GLAUCOMA TREATMENT SYSTEM$14,268
- RESTASIS$11,427
- ALPHAGAN P$7,698
- COMBIGAN$5,400
- Tobradex ST$5,022
- CEQUA$4,119
- Zerviate$3,912
- Flarex$2,646
- TEARCARE SYSTEM$1,120
- Tecnis Symfony IOL$1,000
- Hydrus$675
- Clareon$397
- TYRVAYA$240
- Wavelight Refractive Suite$127
- Rocklatan$125
- Rhopressa$125
How this compares
$171,324 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 93 | $104,887 |
| LumiganBimatoprost | 66 | $38,212 |
| XdemvyLotilaner | 19 | $35,566 |
| CombiganBrimonidine Tartrate/Timolol | 64 | $20,815 |
| Cyclosporine | 44 | $20,351 |
| XiidraLifitegrast | 13 | $11,296 |
| MieboPerfluorohexyloctane/Pf | 15 | $10,812 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 57 | $8,512 |
| RocklatanNetarsudil Mesylat/Latanoprost | 23 | $8,287 |
| VyzultaLatanoprostene Bunod | 17 | $6,521 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 23 | $4,844 |
| Latanoprost | 420 | $4,230 |
| Prednisolone Acetate | 85 | $3,061 |
| Brimonidine Tartrate | 78 | $2,581 |
| Ketorolac Tromethamine | 85 | $1,968 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $147,353 | $163,914223 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $378 | $35,56619 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $84 | $28,62945 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $312 | $8,28723 claims |
| AlconSimbrinza | $1,228 | $4,84423 claims |
| Eyevance Pharmaceuticals LLCFlarex | $11,714 | $1,31511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Bellaire
- Derek CunninghamAustin$940K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$547K
- Luis RojasMcKinney$309K
- Emile FadelAustin$225K
- Bridgitte LeeHouston$222K
- Phillip BrunsonHouston$214K
- Stacie VirdenWaco$164K
- Richard PotvinBurleson$153K
- Celesta Ribas FerreiraCypress$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.